중심장액맥락망막병증에 레이저광응고술 후 생긴 맥락막신생혈관의 유리체강내 베바시주맙 주입술

• 영문명: Intravitreal Bevacizumab Injection for Choroidal Neovascularization Secondary to Laser Photocoagulation for Central Serous Chorioretinopathy
• 발행기관: 대한안과학회
• 저자명: 정종현 문건 김광수 김유철,Jong Hyun Jung, MD, Kun Moon, MD, Kwang Soo Kim, MD, Yu Cheol Kim, MD
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume53,number9, 1352~1356쪽, 전체 5쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2012.09.15

영문 초록

Purpose: To report a case of intravitreal bevacizumab injection for choroidal neovascularization following direct laser photocoagulation for central serous chorioretinopathy. Case summary: A 44-year-old male patient with an 8-month history of metamorphopsia in his left eye visited our clinic and was diagnosed with central serous chorioretinopathy after performing refraction, fundus examination, fluorescein angiography (FAG) and optical coherence tomography (OCT). After 1 month, laser photocoagulation of the leaking point observed on the FAG was performed. After 8 weeks following laser photocoagulation, visual acuity was reduced to 0.4, subretinal hemorrhage accompanied by choroidal neovascularization was observed on FAG and OCT, and an intravitreal bevacizumab injection was administered. After 4 weeks following the injection, macular edema and subretinal hemorrhage decreased, visual acuity increased to 1.0 and was maintained properly. However, after 2 years, the central serous chorioretinopathy recurred and after 3 months, healed spontaneously. Conclusions: Intravitreal bevacizumab injection is a safe and effective treatment for secondary choroidal neovascularization occurring after direct laser photocoagulation for central serous chorioretinopathy. In addition, a single treatment can maintain the patient’s status with no recurrence of choroidal neovascularization over a long-term period. J Korean Ophthalmol Soc 2012;53(9):1352-1356

키워드

Bevacizumab, Central serous chorioretinopathy, Choroidal neovascularization